CKD Bio

종근당바이오 · 063160

Health Care Pharmaceuticals · KOSPI

Small-cap

Market cap US$64.3M (₩88.8B)

Overview

CKD Bio makes fermentation-derived ingredients and pharmaceutical raw materials used in medicines and health products.

Its customers include pharmaceutical manufacturers and related industries that incorporate these materials into finished products. The company is listed on KOSPI, South Korea's main stock exchange.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$116M

▼ −6.8% YoY

Operating profit · FY2025

US$2.6M

▼ −67.1% YoY

Net income · FY2025

−US$2.1M

Turned to loss

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$116.2M(₩160.4B)	US$124.5M(₩171.8B)	US$116M(₩160.1B)
Operating profit	−US$14.6M(−₩20.2B)	US$7.9M(₩11B)	US$2.6M(₩3.6B)
Net income	−US$17.5M(−₩24.2B)	US$6.3M(₩8.7B)	−US$2.1M(−₩2.9B)

Revenue

FY2023US$116.2M
FY2024US$124.5M
FY2025US$116M

Operating profit

FY2023−US$14.6M
FY2024US$7.9M
FY2025US$2.6M

Net income

FY2023−US$17.5M
FY2024US$6.3M
FY2025−US$2.1M

Key ratios (FY2025)

ROE

-2.3%

Debt/Eq

136.1%

Op. margin

2.3%

Net margin

-1.8%

Rev. YoY

▼ −6.8%

Price charts coming soon

Interactive price history isn't here yet. Would you use it?